AI Insight
The SOLSTICE trial evaluated elecoglipron, an oral small molecule GLP-1 receptor agonist, in adults with type 2 diabetes through a multicentre, phase 2b, randomised, placebo-controlled study. Once-daily oral elecoglipron demonstrated reductions in blood glucose levels with a safety and tolerability profile consistent with other GLP-1 receptor agonists at similar development stages. The results support advancing elecoglipron to phase 3 clinical trials.
Why it matters
This represents a potential advancement in diabetes treatment by offering an oral alternative to injectable GLP-1 receptor agonists, which could improve medication adherence and patient convenience. If successful in phase 3 trials, elecoglipron could expand treatment options for the growing population of people with type 2 diabetes who prefer oral medications.
Once-daily oral elecoglipron showed reductions in glycaemia and a safety and tolerability profile consistent with the GLP-1 receptor agonist class at a similar phase of development, supporting continued development with phase 3 trials for people living with type 2 diabetes.